Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Multiple Myeloma Treatment Market

ID: MRFR/Pharma/5354-HCR
200 Pages
Rahul Gotadki
Last Updated: April 15, 2026

Multiple Myeloma Treatment Market Research Report: Size, Share, Trend Analysis By Drug Type (Chemotherapy, Immunotherapy, Targeted Therapy, Steroids), By Treatment Line (First-Line Treatment, Second-Line Treatment, Third-Line Treatment, Subsequent Treatment), By Route of Administration (Oral, Intravenous, Subcutaneous), By End Users (Hospitals, Specialty Clinics, Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Multiple Myeloma Treatment Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type (USD Billion) | |
      1. 4.1.1 Chemotherapy | |
      2. 4.1.2 Immunotherapy | |
      3. 4.1.3 Targeted Therapy | |
      4. 4.1.4 Steroids |
    2. 4.2 Healthcare, BY Treatment Line (USD Billion) | |
      1. 4.2.1 First-Line Treatment | |
      2. 4.2.2 Second-Line Treatment | |
      3. 4.2.3 Third-Line Treatment | |
      4. 4.2.4 Subsequent Treatment |
    3. 4.3 Healthcare, BY Route of Administration (USD Billion) | |
      1. 4.3.1 Oral | |
      2. 4.3.2 Intravenous | |
      3. 4.3.3 Subcutaneous |
    4. 4.4 Healthcare, BY End-user (USD Billion) | |
      1. 4.4.1 Hospitals | |
      2. 4.4.2 Specialty Clinics | |
      3. 4.4.3 Research Institutes |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Bristol-Myers Squibb (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Johnson & Johnson (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Amgen (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Roche (CH) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Novartis (CH) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Takeda (JP) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Celgene (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 GSK (GB) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 AbbVie (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE |
    7. 6.4 US MARKET ANALYSIS BY TREATMENT LINE |
    8. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    9. 6.6 US MARKET ANALYSIS BY END-USER |
    10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY TREATMENT LINE |
    12. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    13. 6.10 CANADA MARKET ANALYSIS BY END-USER |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT LINE |
    17. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    18. 6.15 GERMANY MARKET ANALYSIS BY END-USER |
    19. 6.16 UK MARKET ANALYSIS BY TYPE |
    20. 6.17 UK MARKET ANALYSIS BY TREATMENT LINE |
    21. 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    22. 6.19 UK MARKET ANALYSIS BY END-USER |
    23. 6.20 FRANCE MARKET ANALYSIS BY TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT LINE |
    25. 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    26. 6.23 FRANCE MARKET ANALYSIS BY END-USER |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT LINE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    30. 6.27 RUSSIA MARKET ANALYSIS BY END-USER |
    31. 6.28 ITALY MARKET ANALYSIS BY TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY TREATMENT LINE |
    33. 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    34. 6.31 ITALY MARKET ANALYSIS BY END-USER |
    35. 6.32 SPAIN MARKET ANALYSIS BY TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT LINE |
    37. 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    38. 6.35 SPAIN MARKET ANALYSIS BY END-USER |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT LINE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END-USER |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY TREATMENT LINE |
    46. 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    47. 6.44 CHINA MARKET ANALYSIS BY END-USER |
    48. 6.45 INDIA MARKET ANALYSIS BY TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY TREATMENT LINE |
    50. 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    51. 6.48 INDIA MARKET ANALYSIS BY END-USER |
    52. 6.49 JAPAN MARKET ANALYSIS BY TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT LINE |
    54. 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    55. 6.52 JAPAN MARKET ANALYSIS BY END-USER |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT LINE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END-USER |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT LINE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY END-USER |
    64. 6.61 THAILAND MARKET ANALYSIS BY TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT LINE |
    66. 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    67. 6.64 THAILAND MARKET ANALYSIS BY END-USER |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT LINE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    71. 6.68 INDONESIA MARKET ANALYSIS BY END-USER |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT LINE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY END-USER |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT LINE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    80. 6.77 BRAZIL MARKET ANALYSIS BY END-USER |
    81. 6.78 MEXICO MARKET ANALYSIS BY TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT LINE |
    83. 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    84. 6.81 MEXICO MARKET ANALYSIS BY END-USER |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT LINE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY END-USER |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT LINE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT LINE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END-USER |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT LINE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END-USER |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT LINE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY END-USER |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY TREATMENT LINE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY TREATMENT LINE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY END-USER, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY END-USER, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY END-USER, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY END-USER, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY END-USER, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY END-USER, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY END-USER, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY END-USER, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY END-USER, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY END-USER, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY END-USER, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY END-USER, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY END-USER, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY END-USER, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY END-USER, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY END-USER, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY END-USER, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY END-USER, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY END-USER, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY END-USER, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY END-USER, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY END-USER, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY END-USER, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY END-USER, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY END-USER, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY END-USER, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY END-USER, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY END-USER, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY END-USER, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY TREATMENT LINE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY END-USER, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Steroids

Healthcare By Treatment Line (USD Billion, 2025-2035)

  • First-Line Treatment
  • Second-Line Treatment
  • Third-Line Treatment
  • Subsequent Treatment

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Intravenous
  • Subcutaneous

Healthcare By End-user (USD Billion, 2025-2035)

  • Hospitals
  • Specialty Clinics
  • Research Institutes

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions